- Receptos (RCPT) prices its public offering of 4,433,000 shares of common stock at $40.25/share. Underwriters over-allotment is 664,950 shares. Closing date is June 24.
- Net proceeds will be used to fund the continued development of RPC1063 in clinical trials for relapsing multiple sclerosis and ulcerative colitis, the development of its in-licensed product candidate RPC4046 for eosinophilic esophagitis, other research programs and for general corporate purposes.
From other sites
at Benzinga.com (Feb 27, 2015)
at CNBC.com (Feb 26, 2015)
at Benzinga.com (Feb 23, 2015)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs